Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04399837 |
| Consolidated Lead Sponsor | Boehringer Ingelheim |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 123 participants (ACTUAL) |
| Registered Start Date | 2020-06-04 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Washington University and Siteman Cancer Center | Saint Louis, MO | Open Hospital Dossier -> |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, China | Open Hospital Dossier -> |
| Huashan Hospital, Fudan University | Shanghai, China | Open Hospital Dossier -> |
| The First Hospital of China Medical University | Shenyang, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.